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ABSTRACT 
CLINICAL AND MOLECULAR CHARACTERIZATION OF Burkholderia 
pseudomallei ISOLATED FROM PATIENTS IN HOSPITAL SULTANAH 
NURZAHIRAH (HSNZ) AND TREATMENT OUTCOME 
 
Introduction 
Melioidosis is a potentially fatal disease caused by environmental saprophyte, 
Burkholderia pseudomallei. It is commonly found in soil and surface water in endemic 
regions of Southeast Asia and a common cause of community acquired sepsis and 
pneumonia in the east coast of Peninsular Malaysia.  
Methodology 
This is a prospective cohort study conducted to evaluate the demographic data, clinical 
features and treatment outcome of culture-proven melioidosis at Hospital Sultanah 
Nurzahirah, Terengganu from October 2016 till June 2017. Molecular confirmation of 
B. pseudomallei was performed using a PCR-based assay targeting sctQ gene of the 
TTS1 cluster. Twenty isolates were then subsequently genotyped using DNA 
sequencing of multiple gene loci to determine the genetic relatedness of the strains and 
to correlate the identified genotypes with clinical presentations and outcomes. The 
mortality rates of patients who receive early and appropriate empirical anti-melioidosis 
therapy was compared to those who did not receive appropriate empirical therapy. A 
total of 52 cases were included in the study. Patients’ clinical data were obtained from 
electronic clinical notes.  
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Results 
Ninety six percent of melioidosis patients in this study had at least one underlying 
illness with the most common being diabetes mellitus. Bacteremic melioidosis was seen 
in most patients (n=48, 92.3%). Majority of them had bacteremic localized infection 
(57.7%), followed by disseminated bacteremia (26.9 %) and bacteremia with no focal 
lesion (7.7%). The remaining four patients (7.7%) had non bacteremic localized 
infection. Community acquired pneumonia and fever of unknown origin were the 
common presentation on admission. Lung was the most common organ involved 
(61.5%), followed by liver (15.4%), spleen, central nervous system and soft tissue 
(9.6%), joint and urinary tract (3.8%). All the culture-proven isolates were successfully 
confirmed with PCR. Constructed phylogenetic tree from sequencing of multiple gene 
loci revealed genetic diversity among B. pseudomallei strains, and there is no clustering 
seen with the clinical presentation or outcome. The overall mortality rate was 53.9% 
(n=28/52) and all patients who died had bacteremic melioidosis. Only 15 out of 52 
patients (28.9%) were prescribed appropriate empirical antibiotics, with corresponding 
mortality of 26.7%. The mortality was significantly higher (64.9%) in those who did not 
receive appropriate empirical antibiotic therapy.  
Conclusion 
The clinical manifestations of melioidosis in Terengganu state were diverse and 
comparable to other countries worldwide. B. pseudomallei genotypes showed genetic 
diversity indicating distribution of different strains in the environment. The overall 
mortality rate is high, particularly in those who did not receive early and appropriate 
empirical antibiotics. Thus, a high index of suspicion in endemic country and the early 
use of appropriate empirical antibiotic therapy is crucial to prevent death. 
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ABSTRAK 
CIRI-CIRI KLINIKAL DAN MOLEKULAR Burkholderia pseudomallei YANG 
DIPENCILKAN DARIPADA PESAKIT DI HOSPITAL SULTANAH 
NURZAHIRAH (HSNZ) DAN HASIL RAWATAN 
 
Pengenalan 
Melioidosis adalah penyakit berpotensi maut yang disebabkan oleh saprofit alam 
sekitar, Burkholderia pseudomallei. Ia biasanya ditemui di dalam tanah dan permukaan 
air di kawasan endemik di Asia Tenggara dan merupakan punca utama yang 
menyebabkan penyakit sepsis dan radang paru-paru di Pantai Timur Semenanjung 
Malaysia. 
Tatacara 
Ini adalah kajian kohort prospektif yang dijalankan untuk mengkaji data demografi, ciri-
ciri klinikal dan hasil rawatan penyakit melioidosis yang terbukti melalui kultur di 
Hospital Sultanah Nurzahirah, Terengganu dari Oktober 2016 sehingga Jun 2017. 
Pengesahan molekular B. pseudomallei dilakukan menggunakan ujian berasaskan PCR 
mensasarkan gen sctQ daripada kumpulan TTS1. Dua puluh isolat kemudiannya 
menjalani penentuan genotip menggunakan urutan DNA pelbagai gen loci untuk 
mengkaji kepelbagaian genetik dan untuk mengaitkan genotip yang dikenal pasti 
dengan ciri-ciri klinikal penyakit. Kadar kematian pesakit yang menerima terapi 
empirikal anti-melioidosis yang awal dan sesuai dibandingkan dengan pesakit yang 
tidak menerima terapi empirikal anti-melioidosis yang sepatutnya. Sejumlah 52 kes 
terlibat di dalam kajian ini. Data klinikal pesakit diperoleh daripada nota klinikal 
elektronik. 
Keputusan 
Sembilan puluh enam peratus daripada pesakit melioidosis dalam kajian ini mempunyai 
sekurang-kurangnya satu penyakit kronik, dan faktor risiko yang paling kerap ditemui 
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adalah diabetes mellitus. Melioidosis bakteremik dilihat pada kebanyakan pesakit (n = 
48, 92.3%). Kebanyakan kes mempunyai jangkitan bakteremik setempat (lokal) 
(57.7%), diikuti dengan bakteremik multifokal (26.9%) dan bakteremia tanpa fokus 
yang nyata (7.7%). Empat pesakit (7.7%) mempunyai jangkitan lokal tanpa bakteremia. 
Radang paru-paru yang diperolehi daripada komuniti dan demam berpanjangan yang 
tidak diketahui punca adalah gejala klinikal yang selalu menyebabkan kemasukan ke 
hospital. Paru-paru adalah organ yang paling biasa terlibat (61.5%), diikuti oleh hati 
(15.4%), limpa, sistem saraf pusat dan tisu badan (9.6%), sendi dan saluran kencing 
(3.8%). 
Semua isolat berjaya disahkan dengan PCR. Pokok filogenetik yang dibentuk daripada 
penjujukan pelbagai gen loci mendedahkan kepelbagaian genetik di kalangan isolat B. 
pseudomallei, dan tiada kluster yang dilihat dengan gejala klinikal atau hasilnya. Kadar 
kematian keseluruhan adalah 53.9% (n = 28/52) dan semua pesakit yang meninggal 
mempunyai melioidosis bakteremia. Hanya 15 dari 52 pesakit (28.9%) yang diberikan 
antibiotik empirikal yang sesuai, dengan kematian sebanyak 26.7%. Kematian pesakit 
yang tidak menerima terapi empirik antibiotik yang sesuai adalah jauh lebih tinggi 
(64.9%).  
Kesimpulan 
Kepelbagaian gejala klinikal melioidosis di negeri Terengganu adalah sama dengan 
negara-negara lain di seluruh dunia. Kajian genotip B. pseudomallei menunjukkan 
kepelbagaian genetik yang menunjukkan kewujudan strain yang berlainan dalam alam 
sekitar. Kadar kematian keseluruhan adalah tinggi, terutamanya bagi mereka yang tidak 
menerima antibiotik empirikal yang awal dan sesuai. Oleh itu, indeks kecurigaan yang 
tinggi di negara endemik dan penggunaan awal terapi empirikal antibiotik yang sesuai 
adalah penting untuk mencegah kematian. 
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CHAPTER 1 
1 INTRODUCTION 
 
1.1 Background of the study 
Melioidosis is caused by gram-negative saprophyte, Burkholderia pseudomallei, which is 
present abundantly in soil and surface water, especially in paddy fields, in endemic regions. 
B. pseudomallei is endemic in Southeast Asia and northern Australia, particularly Thailand, 
Malaysia and Singapore (Currie et al., 2008; Puthucheary, 2009; Suputtamongkol et al., 
1999). A study in Pahang has shown the incidence of melioidosis is comparable with that 
in Northern Thailand which is 6.1 per 100 000 populations per year (How et al., 2005).  
B. pseudomallei is a small, gram-negative, oxidase-positive, motile, aerobic bacillus with 
occasional polar flagella. The mode of infection is by percutaneous inoculation, inhalation, 
aspiration or ingestion (Currie, 2015). Melioidosis mainly affects people who have direct 
contact with wet soils and have an underlying predisposition to infection. Susceptibility of 
the host is an important factor in acquiring the disease as it occurs predominantly in 
patients with underlying illness (Puthucheary, 2009). Diabetes mellitus was confirmed to 
be the most common underlying illness associated with melioidosis (60.9%); the other 
common predisposing conditions were chronic renal disease (20.8%), thalassemia (7.3%), 
history of previous trauma or surgery (6.9%), pulmonary tuberculosis (6.3%) and 
hematologic malignancy or solid tumor (4.2%) (Suputtamongkol et al., 1999). 
B. pseudomallei infection causes wide range of clinical presentations. Pneumonia was 
found to be the most common presentation of melioidosis in majority of the studies, but 
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there is a great clinical diversity, ranging from localized infection to fulminant sepsis with 
multi organ involvement. Most patients have bacteremia with severe disseminated disease, 
and high mortality rates despite recent advances in the antibiotic treatment regimens 
(Waiwarawooth et al., 2008). 
Treatment of melioidosis is often difficult and challenging, as response to treatment is often 
disappointingly low despite high dose parenteral antibiotics administration (White, 2003). 
B. pseudomallei is characteristically resistant to penicillin, ampicillin, first and second 
generation cephalosporin, gentamicin, tobramycin and streptomycin. An open-label 
randomized trial in Thailand comparing ceftazidime with conventional therapy (a 
combination of chloramphenicol, trimethoprim-sulfamethoxazole (TMP-SMX) and 
doxycycline) showed that ceftazidime caused reduction in 50% of overall mortality in 
severe melioidosis (White, 2003). Ceftazidime then become the drug of choice for initial 
intensive therapy for melioidosis. Imipenem has also been proved equivalent to ceftazidime 
in a large randomised trial (Simpson et al., 1999). In another study Cheng et al. 
demonstrated that outcomes of patient with melioidosis treated with meropenem were 
similar to those treated with ceftazidime (Cheng et al., 2004). 
The recommended duration of intensive therapy is at least 10 to 14 days. Longer treatment 
course is required for critically ill patients, or for patients with extensive pulmonary 
disease, deep seated collections or organ abscess, osteomyelitis, septic arthritis and 
neurological involvement (Dance, 2014; White, 2003). Subsequent eradication therapy is 
necessary after the initial intensive phase to prevent recrudescence or relapse of 
melioidosis. B. pseudomallei is a facultative intracellular pathogen that can invade and 
replicate inside various cells, including polymorphonuclear leukocytes and macrophages. 
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The ability of B. pseudomallei to survive intracellularly explains the tendency for the 
patient to get relapse or recurrent disease (Dance, 2014; White, 2003).  
1.2 Rationale of the study 
Melioidosis is a disease of the rainy season in endemic areas like Malaysia. The association 
between surface water and melioidosis is supported by its association with monsoonal 
rains, and with occupational and recreational exposure to water and soil (Cheng and Currie, 
2005). Terengganu state, which is located on the east coast of Peninsular Malaysia, has a 
heavy monsoon season from November to March every year. Thousands of people are at 
risk of contracting B. pseudomallei infection, which is a great public health concern and an 
important cause of community acquired sepsis in the east coast of Peninsular Malaysia. 
However, not many publications on melioidosis reported from Malaysia, in particular 
Terengganu state.  
Melioidosis has a diverse spectrum of clinical presentations and can affect any organ. It is 
important to define the local demographic profiles, clinical characteristics and outcome of 
melioidosis because of regional differences that have been described in the prevalence of 
organ involvement. This study aimed to determine the demographic profiles, clinical and 
molecular characteristics, and treatment outcome of patients with melioidosis who attended 
Hospital Sultanah Nur Zahirah (HSNZ), Terengganu.  
B. pseudomallei is easily recovered on standard culture medium but may be misidentified 
as B. cepacia, B. thailandensis, Pseudomonas stutzeri or other Pseudomonas species. 
Molecular methods are more accurate in species identification but are expensive for routine 
laboratory use.
 
In this study, molecular method has been used to give accurate species 
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identification. The molecular identification is based on detection of sctQ gene which is 
located in Type III secretion system (TTS1) gene cluster, on chromosome no II. TTS 1 is a 
toxin delivery mechanism that allows pathogenic bacteria to inject toxic substances into 
cytoplasm of host’s cells. A study in France showed amplification of orf11, a gene region 
located in the TTS1 is seen only in B. pseudomallei (Thibault et al., 2004). 
Molecular typing that shows clonality of isolates in animal and human clusters has revealed 
that the same outbreak strain can cause different clinical presentations, with host factors 
being most important in determining the severity of the disease (Bennett et al., 2014). Two 
studies, however, have suggested that clinical presentation or outcome may depend on the 
strain type. A study by Pitt et al. found that certain ribotypes appeared to be associated with 
a higher mortality or risk of relapse (Pitt et al., 2000). Another study by Norton et al. in 
1998 that utilized multilocus enzyme electrophoresis (MLEE) and RAPD analysis 
suggested that soft tissue infections were restricted to one cluster and respiratory and 
neurological infections were seen in another cluster. In this study genotyping of B. 
pseudomallei by DNA sequencing of multiple gene loci has been performed to determine 
the genetic relatedness of the strains.  
Early diagnosis of melioidosis and administration of appropriate antibiotic therapy is 
necessary as acute melioidosis is life threatening, especially in patient with bacteremia. 
Bacteremia and overall mortality rates have been high. More than half of the patients died 
within two days after admission, before bacterial cultures became positive (Dharakul and 
Songsivilai, 1999).  
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A retrospective study done in a tertiary hospital found that death due to melioidosis among 
bacteremic melioidosis was associated with shorter hospitalization, no identified 
underlying disease, and no anti-melioidosis therapy (Deris et al., 2010). Eight out of 27 
patients (29.6%) were not given anti-melioidosis therapy because identification of the 
causative agent was not made until after the patient died. Lack of clinical suspicion leading 
to delay in treatment was also described in a retrospective study done among paediatric 
melioidosis patients in Pahang, Malaysia (How et al., 2005). Only one out of seven 
(14.3%) paediatric bacteremic melioidosis patient was treated empirically with active drugs 
for melioidosis. In this study, the mortality rates of patients who receive early and 
appropriate empirical anti-melioidosis therapy were compared to those with delayed 
empirical anti-melioidosis therapy and those who never received appropriate empirical 
antibiotic.  
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1.3 Literature review 
1.3.1 History and taxonomy of B. pseudomallei  
Burkholderia pseudomallei was discovered in 1911 when a pathologist; Alfred Whitmore 
and his assistant Krishnaswami noticed ‘undescribed glanders-like illness’ during routine 
post mortem examination of morphine addict corpse in Rangoon. Glanders is an abscess-
forming infection in horses caused by Burkholderia mallei, which can occasionally affect 
human (White, 2003). In 1913 Fletcher discovered the disease in laboratory animals at the 
Institute for Medical Research (IMR) in Kuala Lumpur, Malaysia and later in 1917 Stanton 
first described similar infection in human patient from Kuala Lumpur. Both authors wrote a 
short monograph on the disease and its sporadic occurrence in Malaya up to 1932 
(Puthucheary, 2009).  
The term ‘melioidosis’ was created by Stanton and Fletcher in 1921, which derived from 
the Greek words ‘melis’ meaning ‘a distemper of assess’ and ‘eidos’, resemblance. This 
was because the disease resembles glanders, a chronic and debilitating disease of equines 
caused by B. mallei. The new organism could be differentiated from B. mallei by its 
relatively rapid growth, motility, and the lack of the Strauss reaction when it was injected 
into guinea pigs. They correctly predicted that this new bacterium was closely related to the 
organism that caused glanders, a finding that has only recently been confirmed by 
molecular studies. 
During the last century this gram negative saprophytes has been variously known as 
Bacillus pseudomallei, Bacillus whitmorii, Malleomyces pseudomallei and Pseudomonas 
pseudomallei. With the molecular evolution of bacterial classification, Yabuchi and co-
workers proposed a new genus Burkholderia in 1992 (named after Walter Burkholder who 
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first described Burkholderia cepacia). The species pseudomallei, along with six other 
species were transferred to the new genus and became Burkholderia pseudomallei (Cheng 
and Currie, 2005). In the latter half of 20
th
 century, B. pseudomallei emerged as an 
infectious disease of major public health importance in Southeast Asia, (including 
Thailand, Malaysia and Singapore) and Northern Australia. B. pseudomallei has been 
designated a tier 1 overlap select agent by the U.S. Centre for Disease Control and 
Prevention (CDC) and U.S Department of Agriculture and Animal and Plant Healh 
Inspection Service (USDA/APHIS) (Hemarajata et al., 2016). 
1.3.2 Epidemiology of Melioidosis 
Melioidosis is regarded endemic to Southeast Asia and Northern Australia, especially in 
the tropical region which correspond approximately to the latitude of between 20˚N and 
20˚S (Cheng and Currie, 2005). Dance et al. noted that published case report and series are 
likely to represent only the ‘tip of iceberg’ as culture facilities are not available in most of 
rural tropics where in the infection is likely to be prevalent (Dance, 2000).     
Melioidosis is predominantly occurring during the rainy season in endemic areas. It mainly 
affects people who have direct contact with wet soils and have underlying predisposition to 
infection (White, 2003). B. pseudomallei has been isolated from soil and water from all 
states in West Malaysia by Strauss and co-workers in 1969. Soil moisture was found to be 
an important factor in the isolation of the organism; this is because the water table rises to 
the surface carrying with it the bacteria that normally reside deep inside the soil 
(Puthucheary, 2009). The risk of disease is roughly proportional to the concentrations of 
organisms in the soil. 
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Melioidosis may present at any age; however peak incidence was found to be in 4
th
 and 5
th
 
decade of life, coinciding with development of underlying predisposing illness. In the 
northeast Thailand, the average annual incidence was estimated to be 4.4 per 100 000, but 
this number is increasingly steadily with the demographic transition, since improved health 
services and economic condition allow people to live longer (White, 2003). 
Most of the population in endemic areas of Southeast Asia have antibodies to B. 
pseudomallei, but these antibodies have not been shown to be protective (Patel et al., 
2011). Melioidosis may result either from host defence failure due to underlying disease or 
drugs, or from an encounter of especially large inoculum, for instance during major trauma 
or near-drowning (White, 2003). 
 
 
Figure 1.1: Worldwide distribution of melioidosis. Adapted from (Currie, 2015). 
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1.3.3 Risk factors for melioidosis 
Burkholderia pseudomallei behaves as an opportunistic pathogen; as exposure to the 
organism is widespread in endemic area and yet the disease is not that common. It occurs 
predominantly in immunocompromised individuals with underlying disease for instance 
diabetes mellitus and renal disease. This suggests that susceptibility of the host is an 
important factor in acquiring the disease. A prospective melioidosis study over 25 years in 
Australia reported that 113 of the 115 deaths cases were directly attributed to one or more 
risk factors (Currie et al., 2010).  
Diabetes mellitus is the most frequent predisposing condition for melioidosis. Up to 50% of 
patients with melioidosis have diabetes mellitus, usually Type II diabetics with 
uncontrolled blood glucose level before infection (White, 2003). In Malaysia, Northeast 
Thailand and Singapore, diabetes mellitus was the most frequently reported predisposing 
condition with up to 60% of patients having pre-existing or newly diagnosed type 2 
diabetes (Puthucheary, 2009).  In Malaysia about 70-89% of melioidosis patients had 
diabetes mellitus (Deris et al., 2010; Hassan et al., 2010; How et al., 2005). 
Other recognized risk factors in acquiring melioidosis include chronic renal failure, 
malignancy, immunosuppressive treatment, in particular steroids, alcoholism, occupational 
exposure, thalassemia, chronic liver and lung disease and neutropenia (Dance, 2000; 
Puthucheary, 2009). The underlying immune dysfunction in the aforementioned risk factors 
lead to wide range of immune deficits including phagocytic defects, diminished humoral 
and cellular immune responses, and diminished cytokine production.  
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1.3.4 Modes of acquisition 
Melioidosis is a disease involving all age group but commonly occurs in people between 
the ages of 40 to 60 years. There are three recognized modes of acquisition for B. 
pseudomallei; inhalation of contaminated dust, ingestion and direct inoculation 
(Puthucheary, 2009). The modes of acquisition as well as size of inoculum are likely to be 
responsible for the pattern and severity of disease. Conditions that can cause exposure to 
high inoculum of the bacteria, such as near drowning, are associated with shorter 
incubation period. Inoculation is now believed to be the major mode of acquisition. Minor 
wounds to the feet of rice farmers are common during planting and harvesting season. 
Occasional unusual modes of transmission have been reported in the literature; including 
lab acquired infection, sexual transmission, vertical and perinatal transmission (Cheng and 
Currie, 2005). 
1.3.5 Pathogenicity  
1.3.5.1 Virulence factors  
B. pseudomallei is a resilient bacterium that can survive in a very harsh environment. In 
human, it behaves as an opportunistic intracellular pathogen which multiplies inside 
phagocytic and non-phagocytic cells. It may remain latent for many years before 
reactivation into active infection (Puthucheary, 2009). The structural and functional aspect 
of B. pseudomallei components, their regulation and role in pathogenesis are still 
incompletely or poorly understood. Examples of B. pseudomallei virulence gene include 
those encoding for proteases, lipases, lecithinases, catalase, peroxidase, hemolysis, 
cytotoxins, adhesions, inasins, fimbriae and pili and secretion systems type II, III and VI 
(Sarovich et al., 2014). 
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B. pseudomallei is able to polymerize actin, and to spread from cell to cell, causing cell 
fusion and the formation of multinucleated giant cells. It also produces a highly hydrated 
glycocalyx polysaccharide capsule, which helps to form slime. This capsule facilitates 
formation of micro colonies and creates protection from penetration of antibiotics 
(Yabuuchi et al., 1992). In addition, B. pseudomallei also possesses a unique fusogenic 
type-VI secretion system that is required for cell to cell spread and virulence in mammalian 
hosts. It is one of the first Proteobacteria identified to have an active type-VI secretion 
system and the only organism identified that contains up to six different type-VI secretion 
systems. The bacterium also expresses a toxin called lethal factor 1 (Kespichayawattana et 
al., 2000; Toesca et al., 2014; Wiersinga et al., 2006).  
B. pseudomallei is transmitted from environment to human host and attached to the 
epithelial cell layers of either the abraded skin, the respiratory tract mucosa or 
gastrointestinal tract mucosal layers. The attachment is aided by the bacterial capsule and 
type 4 pili, followed by formation of pili-mediated micro colonies once the optimal 
epithelial attachment is obtained (Galyov et al., 2010). Type III secretion system effectors 
assist bacterial invasion by disrupting the phagosomal membrane and facilitate the bacterial 
escape into the host cytosol (Lazar Adler et al., 2009).  
1.3.5.2 Role of host immune response 
B. pseudomallei appears to be resistant to serum bactericidal components. Even though the 
alternative complement pathway is activated, resulting in phagocytosis, it is to be able to 
evade phagosome-lysosome fusion and destroy the phagosome membrane as soon as 15 
minutes after ingestion. It is also resistant to the effects of the terminal complement 
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membrane attack complex. It is established that B. pseudomallei can survive and multiply 
within professional phagocytes, including macrophage or monocyte and neutrophil cell 
lines. The comorbidities recognized as risk factors for melioidosis such as diabetes mellitus 
has been demonstrated to cause impaired chemotaxis, phagocytosis, oxidative burst and 
killing activity. Similar defects have been observed in association with chronic renal 
failure, thalassemia and high alcohol intake (Cheng et al., 2007). 
B. pseudomallei induces humoral and cell-mediated responses during disease stage. 
Individual who were exposed to B. pseudomallei develop IgA, IgM and IgG antibodies that 
are increased during acute infection and their levels correlate with the severity of disease. 
High levels of antibodies remain elevated for years in patient’s serum after meliodosis 
recovery, suggesting continuous exposure to B. pseudomallei or sequestration of bacteria in 
intracellular sites of latency (Gan, 2005). It is assumed that B. pseudomallei survival in 
professional phagocytes play a role in the site of latent infection, little is known regarding 
the precise localization of latent intracellular B. pseudomallei. 
During severe melioidosis, the levels of pro-inflammatory cytokines and immunoregulatory 
cytokines indicate an extensive activation of cellular immune response (Cheng et al., 
2007). Despite cell-mediated immune response in the neutralizing and protection against 
disease progression, there is no definitive evidence for the protective immunity against 
melioidosis which allow reinfection occurrence with a different B. pseudomallei strain after 
successful treatment (Currie, 2015).  
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1.3.6 Clinical manifestations 
B. pseudomallei causes wide range of clinical signs and symptoms, thus has been dubbed 
‘the great mimicker’. The symptoms and signs of melioidosis can range from 
asymptomatic, benign localized infection to a rapidly fulminant and fatal septicemia. 
Severe melioidosis may present as disseminated septicemia, non-disseminated septicemia 
or localized infection. Clinical classification of melioidosis has been controversial since 
melioidosis is a multi-system disease (Puthucheary, 2009). The type of presentation may be 
influenced by the magnitude of exposure, mode of acquisition, host factors and risk factors. 
Recognition of melioidosis based on clinical presentation can be challenging, and a delay 
in diagnosis can result in fatality.  
Melioidosis is divided into acute and chronic cases based on the onset of the illness. Acute 
cases are those patients with symptoms of less than two months. In most patient, mean 
incubation was nine days (range 1 to 21 days). Chronic melioidosis is defined as an illness 
where symptoms have lasted for longer than  two months at presentation (Foong et al., 
2014). 
Pneumonia is the most common presentation of melioidosis accounting up to half of all 
cases, but there is a great clinical diversity, ranging from localized skin ulcers or abscess to 
fulminant sepsis with multiple skin and soft tissue, deep organ or musculoskeletal 
abscesses (Waiwarawooth et al., 2008). Almost any organ system may be affected 
including lungs, kidneys, spleen, liver, prostate, parotids and brain (Foong et al., 2014). 
A study in HUSM in 2009 revealed that the main clinical presentation was fever (83.2%), 
with 66.7% of patients had lung involvement. Other presentations include cough, scrotal 
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swelling, Fournier’s gangrene, urinary retention, neck cellulitis, abdominal distention, 
jaundice, vomiting and seizure (Deris et al., 2010). Chou et al. conducted a retrospective 
study at Tainan Municipal Hospital, and found that the lungs were the most common site of 
infection in patients with bacteremic melioidosis and rapidly progressive community 
acquired pneumonia was major cause leading to mortality (Chou et al., 2007). The most 
common site of infection was the lung (70%), followed by the genitourinary tract (13.3%), 
peritoneum (6.7%), meninges (3.3%), skin (3.3%) and aorta (3.3%). There were also 20% 
of cases without a primary site being identified.  
1.3.7 Laboratory Diagnosis 
Laboratory diagnosis of B. pseudomallei includes conventional, molecular and 
immunological methods. 
1.3.7.1 Conventional Identification 
Isolation of B. pseudomallei from patients remains the ‘gold standard’ in the diagnosis of 
melioidosis. The organism is non-fastidious and will grow on almost all routine media, but 
with non-sterile specimens, B. pseudomallei can be overgrown by contaminating flora due 
to paucity of the organisms especially from deep-seated abscess. Cultures typically become 
positive in 24 to 48 hours (this rapid growth rate differentiates the organism from B. mallei, 
which typically takes a minimum of 72 hours to grow).  
The rate of successful isolation of B. pseudomallei from non-sterile sites like sputum or pus 
aspirate is increased if they are placed into colistin-containing transport media called 
Ashdown’s broth or directly plated onto gentamicin-containing Ashdown agar. Both types 
of media facilitate the selective growth of B. pseudomallei and inhibit the growth of 
contaminants (Currie, 2015; Puthucheary, 2009). The use of selective media, such as Mac-
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Conkey agar, Ashdown agar, B. pseudomallei selective agar (BPSA), or B. cepacia 
selective agar (BCSA), is recommended, particularly for tissues or any specimen expected 
to be contaminated with normal flora, such as respiratory secretions. 
B. pseudomallei colonies are initially smooth, however become wrinkled with prolonged 
incubation after three to five days. It has a metallic appearance, and possesses an earthy 
odour. It appears as colorless lactose non-fermenter colonies on MacConkey agar. On 
Gram staining, the organism is a Gram-negative rod with a characteristic "safety pin" 
appearance (bipolar staining). It exhibits bipolar staining due to accumulation of poly-β-
hydroxybutyrate. It is oxidase positive, motile, grow on 42˚C and produce neutral-alkaline 
reaction on triple sugar iron biochemical test. On sensitivity testing, the organism appears 
highly resistant (it is innately resistant to a large number of antibiotics including colistin 
and gentamicin) and that again differentiates it from B. mallei, which is in contrast, 
exquisitely sensitive to a large number of antibiotics.  
Conventional screening panel can be combined with substrate utilization kits, such as 
Vitek-1 and Vitek-2 systems (bioMérieux, France) and the analytical profile index system 
for non-enterobacteriaceae (API 20 NE system). API 20 NE (bioMérieux, France) is a 
standardized system for non-enteric gram-negative bacteria. It comprises of eight 
conventional tests (nitrate, tryptophan, glucose acidification, arginine, urea, esculin, gelatin 
and PNPG) and 12 assimilation test (glucose, arabinose, mannose, mannitol, N-
acetylglucoseamine, maltose, gluconate, caprate, adipate, malate, citrate and pheny lactate) 
supplied with background database. Every test is assigned a digit so that the complete 
profile of 20 digits is given in the identification database which will give the most probable 
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identification. The API 20 NE has high accuracy rate and easy to handle (Weissert et al., 
2009). 
Vitek 2 system showed sensitivity of 69% with common low discrimination identification 
finding, whilst API 20 NE correctly identified 87% of 56 and 99% of 800 isolates 
respectively in two studies (Foong et al., 2014)x. In general, API 20NE detection rate of B. 
pseudomallei isolates in Thailand was up to 99% and in Australia was 37-98% (Hoffmaster 
et al., 2015).  In another study, Vitek 2 GN card detected 47 (78.3%) out of 60 confirmed 
clinical isolates which was lower than that of API 20 NE that was 52 (86.7%) (Deepak et 
al., 2008). 
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Figure 1.2:  Colony of B. pseudomallei on MacConkey agar 
1.3.7.2 Molecular diagnosis 
B. pseudomallei may be misidentified as B. cepacia, B. thailandensis, P. stutzeri or other 
Pseudomonas species. Molecular methods are more accurate in species identification but 
are expensive for routine laboratory use. Several molecular methods were developed for 
the identification of B. pseudomallei, including gene sequencing, DNA microarray, 
isothermal DNA amplification and polymerase chain reaction (PCR). 
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PCR-based techniques have been very useful in diagnosis of melioidosis, however it 
requires some level of instrumentation and expertise. Culture-based methods are time-
consuming and may lead to misidentification while serology-based tests which are both 
faster and less sophisticated may be rendered less reliable in view of presence of high 
background titre levels in endemic country and cross-reactivity with other organisms.   
Various PCR assays have been developed for detection of B. pseudomallei. The gene 
targets include the orf2 gene of TTS1gene cluster (Winstanley and Hart, 2000), 16S 
ribosomal RNA (rRNA) (Brook et al., 1997; Dharakul et al., 1999),  16S-23S rRNA 
(Kunakorn et al., 2000), 23S rRNA (Tkachenko et al., 2003), serine metalloprotease 
(mprA) (Neubauer et al., 2007), lipopolysaccharide (LPS) gene (Rattanathongkom et al., 
1997), flagellin C (fliC) and ribosomal protein subunit S21 (rpsU)  (Tomaso et al., 2005). 
The sensitivity and specificity of PCR is generally excellent when tested against purified 
bacterial DNA, but the sensitivity decline when testing clinical specimen. This discrepancy 
might be attributed to the presence of DNA inhibitors in the clinical specimen (Kaestli et 
al., 2012).  
1.3.7.3 Molecular typing 
Various molecular typing tools have been performed to investigate the epidemiology of 
melioidosis and to explore genetic relatedness among B. pseudomallei isolates, including 
pulsed-field gel electrophoresis (PFGE), random amplified polymorphic DNA (RAPD) 
analysis, and ribotyping. However, these methods are not well suited for inter-laboratory 
comparisons, and molecular typing procedures that use nucleotide sequence data rather 
than DNA fragment patterns are increasingly being used (Godoy et al., 2003).  
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MLST is based on allelic differences present at seven housekeeping genes, and is ideal for 
genetic analysis due to its reproducibility, low rate of genetic change in the allelic sites and 
allows for comparison between strains typed at different laboratories through an internet-
based database (http://www.pubmlst.net/) (Cheng and Currie, 2005). The different 
sequences at each of the seven loci are assigned different allele numbers, and the series of 
integers that corresponds to the allele numbers at the seven loci define the allelic profile of 
a strain. MLST has become an established technique for the unambiguous and precise 
characterization of isolates and for epidemiological purposes (Godoy et al., 2003). 
MLST appears to have a discriminatory ability similar to that of PFGE, but provides data 
that are much more easily compared than PFGE data and is ideal for comparison of isolates 
characterized in different laboratories and for the detection of strains with international 
distribution (Godoy et al., 2003). 
1.3.8 Treatment of melioidosis 
B. pseudomallei is intrinsically resistant to wide range of antibiotics which include some β 
lactam, aminoglycosides and macrolides. Therapeutic approach of melioidosis comprise of 
two phases; acute phase treatment to resolve severe acute infection to avoid death due to 
overwhelming sepsis. The second maintenance phase treatment is administered for 
eradication of residual intracellular infection to avoid relapse (Currie, 2015).  Current 
international guidelines suggest intensive phase treatment with a minimum of 10 to 14 days 
of intravenous antibiotics followed by three to six months of oral antibiotics for eradication 
phase (Pitman 2015). Options for the intensive phase include ceftazidime or carbapenem; 
whilst options for the eradication phase include trimethoprim-sulfamethoxazole (TMP-
SMX), doxycycline or amoxicillin-clavulanate. 
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For acute melioidosis, treatment with intravenous ceftazidime 50 mg/kg (up to 2 g every 8 
hours) has been recommended in uncomplicated infection. In cases of severe acute 
infections with central nervous system involvement, treatment failure or persistent 
bacteremia, imipenem and meropenem 25 mg/kg (up to 1 g every 8 hours) are given 
intravenously. The duration of intensive phase may be extended to more than 4 weeks in 
severe case of melioidosis (Dance, 2014). Longer treatment is required for critically ill 
patients, or for extensive pulmonary disease, deep seated collections or organ abscess, 
osteomyelitis, septic arthritis and neurologic melioidosis.  In the past 20 years, several 
studies have shown that the mortality rate has been reduced to 19-37% with high dose 
ceftazidime or imipenem therapy for at least 2 weeks. White et al. demonstrated that 
ceftazidime could reduce overall mortality by 50% in a randomized control trial while 
Cheng et al. demonstrated that outcomes of patient with melioidosis treated with 
meropenem were similar to those of ceftazidime-treated patient (Cheng et al., 2004; White, 
2003).  
Carbapenems kill B. pseudomallei more rapidly than cephalosporins.  High dose imipenem 
has been shown in a comparative trial in Thailand to be at least as effective as ceftazidime 
for severe melioidosis, with no differences in mortality rate and fewer treatment failures in 
those given imipenem (Simpson et al., 1999). Observational data from Australia have 
suggested that meropenem produces better outcomes in severe melioidosis than ceftazidime 
which has led to the recommendation that meropenem is the drug of choice for melioidosis 
in septic shock (Cheng et al., 2004). 
Waiwarawooth et al. has conducted a retrospective study in 2008 to evaluate the 
epidemiological data and clinical outcome of culture-proven melioidosis at Chonburi 
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Hospital, Thailand, form January 2001 to December 2006. The case fatality rate was found 
to be high, particularly in patient who had acute severe lung infection with bacteremia, and 
treated with inappropriate antibiotic therapy. The overall mortality rate was 47%. Male sex, 
bacteremia, lung infection, acute onset of disease and treatment with inappropriate 
antibiotics were the factors found to significantly correlate with higher mortality rate. The 
mortality was 63.41% in those who received inappropriate therapy; in which the mortality 
was 31.8% in those receiving delayed appropriate therapy, and 100% mortality in those 
who never received appropriate therapy. The mortality was lower in patients who received 
appropriate antibiotic therapy. Clinical awareness, high index of suspicion and prompt 
effective treatment of high-risk patients was reported reduce the mortality (Waiwarawooth 
et al., 2008)  
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1.4 Objective(s) of the research  
General objective: 
To study clinical and molecular characteristics, antibiotics susceptibility patterns and 
treatment outcomes of Burkholderia pseudomallei infection in hospitalized patients in 
Hospital Sultanah Nur Zahirah (HSNZ). 
 
Specific objectives: 
1. To determine the demographic data and clinical characteristics of patients with 
melioidosis in HSNZ. 
2. To identify Burkholderia pseudomallei isolates using molecular technique (PCR). 
3. To perform genotyping of Burkholderia pseudomallei isolates and to correlate with 
clinical presentation. 
4. To determine the antibiotic susceptibility pattern of Burkholderia pseudomallei 
isolates in HSNZ. 
5. To determine the association between treatments outcome of patient with 
melioidosis in HSNZ with empirical antibiotic therapy received. 
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Data Analysis 
1.5 Flow chart of the study 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Antibiotic 
susceptibility 
Demographic data 
Clinical 
characteristics Molecular 
confirmation by PCR 
and Genotyping  
Clinical manifestation 
Treatment outcome 
All clinical specimens from HSNZ 
that were culture positive for 
Burkholderia pseudomallei 
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CHAPTER 2 
2 METHODOLOGY 
2.1 Study design 
A descriptive cross-sectional study was conducted at Hospital Sultanah Nur Zahirah 
(HSNZ) from October 2016 until June 2017.  
2.2 Reference population 
All Burkholderia pseudomallei isolated in HSNZ. 
2.3 Source population 
All B. pseudomallei isolates isolated in HSNZ from October 2016 until June 2017. 
2.4 Sampling frame 
Patients who received treatment in HSNZ; whom clinical specimen grew B. pseudomallei 
collected from October 2016 until June 2017 that fulfil the inclusion and exclusion criteria. 
2.5 Inclusion criteria  
All confirmed B. pseudomallei isolated from any clinical specimens including blood, 
sputum, pus, swab, tissue, urine and CSF.  
2.6 Exclusion criteria 
Repeated isolate of B. pseudomallei discovered from similar or different sites during the 
same admission or within four weeks period are excluded. 
